Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

PHASE3TerminatedINTERVENTIONAL

Enrollment

458

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

ObesityDiabetes Mellitus Type 2

Interventions

DRUG

Rimonabant

Tablet, oral administration

DRUG

Placebo (for Rimonabant)

Tablet, oral administration

DRUG

Anti-diabetic monotherapy

Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period

Trial Locations (1)

Sanofi-Aventis Administrative Office, Tokyo